Adenoid Cystic Carcinoma

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the following presentations related to emiltatug ledadotin (Emi-Le; XMT-1660), Mersana’s B7-H4-directed Dolasynthen ADC, will be given at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting taking place May 30-June 3, 2025 at McCormick Place, Chicago, IL: Oral Presentation Details Title: Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin (Emi-Le), a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate Rapid Oral Session Title: Developmental Therapeutics Date and Time: Monday, June 2, 2025 from 8:00-9:30 a.m. CT Abstract Number: 3009 Presenter: Erika Hamilton, M.D., Director Breast Cancer Research Program, Sarah Cannon Research Institute in Nashville, Tennessee This presentation will include clinical data from dose escalation and backfill cohorts across tumor types from the ongoing Phase 1 clinical trial of Emi-Le. Poster Presentation Details Title: Emiltatug Ledadotin (Emi-Le): A B7-H4-Directed Dolasynthen Antibody-Drug Conjugate (ADC) Being Investigated in Phase 1 Dose Expansion in Patients with Triple Negative Breast Cancer Who Received at Least One Prior Topoisomerase-1 Inhibitor ADC Poster Session Title: Breast Cancer - Metastatic Date and Time: Monday, June 2, 2025 from 9:00-12:00 p.m. CT Abstract Number: TPS1141 Presenter: Hyo Han, M.D., H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple negative breast cancer (TNBC) who have received one to four prior treatment lines, including at least one topoisomerase-1 inhibitor ADC. Additionally, as previously announced, an oral presentation regarding Emi-Le will be given at the ESMO Breast Cancer 2025 Annual Congress in Munich, Germany on Thursday, May 15, 2025. This presentation will focus on TNBC clinical data from dose escalation and backfill cohorts from the Phase 1 clinical trial of Emi-Le. About Emi-Le Emi-Le is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin payload with controlled bystander effect. This candidate is being investigated in a Phase 1 dose escalation and expansion trial in patients with solid tumors, including breast, endometrial and ovarian cancers as well as adenoid cystic carcinoma type 1. In the initial clinical data that were reported as of a December 13, 2024 data cutoff, Emi-Le was observed to be generally well tolerated with differentiated safety and tolerability profile. Additionally, confirmed objective responses were observed across all enrolled tumor types, including in patients with triple negative breast cancer (TNBC) who had previously been treated with a topoisomerase-1 inhibitor (topo-1) ADC. The U.S. Food and Drug Administration has granted two Fast Track designations to Emi-Le for the treatment of 1) adult patients with advanced or metastatic triple-negative breast cancer, and 2) advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including TNBC, who have received a prior topo-1 ADC. For more information about Mersana’s ongoing Phase 1 trial of Emi-Le, please visit clinicaltrials.gov (NCT05377996). About Mersana Therapeutics Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com. Contact: Jason Fredette 617-498-0020 jason.fredette@mersana.com

April 17, 2025 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR. Poster presentation details: Title: Elraglusib, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer Session Title: Phase II Clinical Trials 2 Session Date and Time: April 29, 2025, 2:00 PM - 5:00 PM Location: Poster Section 50 Abstract Presentation Number: CT212 "Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid Cystic Carcinoma (ACC) population with nuclear GSK-3β overexpression given this difficult to treat and rare cancer type", said Dr. Glenn Hanna, Director of the Center for Cancer Therapeutic Innovation (CCTI), the early drug development program at Dana Farber Cancer Institute, who led the team conducting this clinical study. Separately, an independent research group led by Dr. Wafik S El-Deiry from Legorreta Cancer Center at Brown University will present a poster demonstrating the synergistic effects of elraglusib in combination with ONC206 or ONC212, investigational compounds from Jazz Pharmaceuticals plc. Poster presentation details: Title: Elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor in combination with imipridones for treatment of solid cancer Session Title: Drug Combination Strategies for Cancer Treatment Session Date and Time: April 28, 2025, 9:00 AM - 12:00 PM Location: Poster Section Poster Section 19 Abstract Presentation Number: 1693 About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. The content above comes from the network. if any infringement, please contact us to modify.

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, Linda C. Bain, to its Board of Directors. Ms. Bain is a Venture Partner at Atlas Venture and currently serves as a Board Advisor to Remix Therapeutics. “Linda brings more than 20 years of financial, operational and executive leadership success at innovative life science companies,” said Matt Patterson, Chairman of Remix Therapeutics Board of Directors. “Her substantial knowledge and experience successfully managing organizations through significant periods of growth will be invaluable to support Remix as it advances its innovative clinical-stage and discovery programs.” “Having partnered with Linda in her role as Board Advisor to Remix, we are excited to have her join our Board of Directors,” said Pete Smith, PhD, Co-Founder and Chief Executive Officer of Remix Therapeutics. “Linda’s impressive track record of leading financial and operational strategy for both private and publicly held biopharmaceutical companies will be beneficial to Remix’s evolution and achieving our goals.” Prior to Atlas Venture, Ms. Bain served as Chief Operating Officer (COO) and Chief Financial Officer (CFO) of Mariana Oncology and oversaw the company’s acquisition by Novartis in 2024 for $1B upfront and up to $750M in potential milestone payments. She has raised nearly $1B in capital for public and private life science companies over the past 10+ years. Prior to Mariana Oncology, Ms. Bain served as CFO of Codiak BioSciences, CFO of Avalanche Biotechnologies, and Vice President of Finance, Business Operations, and Treasurer at bluebird bio. She previously held senior roles at Genzyme, Fidelity Investments, AstraZeneca and Deloitte & Touche. She is currently on the Board of Directors of Arvinas, Autolus Therapeutics and Hemab Therapeutics.“I am thrilled with the opportunity to contribute my skills and experience to a Company at the forefront of tackling disease drivers with a novel approach, modulating RNA processing with small molecules,” said Ms. Bain. “I look forward to joining the Remix Board of Directors and working with the team to best position the Company to deliver on this important mission and advancing new options for patients in great need of new treatments.” About Remix TherapeuticsRemix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). For more information visit www.remixtx.com. Contacts: Media Contact:Lisa BuffingtonBuffington Commslbuffington@remixtx.com Investor Contact:Will O'Connor Precision AQWill.OConnor@precisionaq.com